{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:21:34Z","timestamp":1768288894957,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","physicamedica.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physica Medica"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejmp.2020.03.004","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T18:32:44Z","timestamp":1584469964000},"page":"16-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-8472","authenticated-orcid":false,"given":"Nicholas","family":"Hardcastle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-4046","authenticated-orcid":false,"given":"Tomas","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.R.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmp.2020.03.004_b0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clon.2017.11.010","article-title":"Single fraction stereotactic ablative body radiotherapy for oligometastasis: outcomes from 132 consecutive patients","volume":"30","author":"Gandhidasan","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0010","first-page":"1","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"6736","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmp.2020.03.004_b0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0020","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.ejmp.2020.03.004_b0025","first-page":"1","article-title":"Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy processes for ongoing quality improvement","author":"Solberg","year":"2011","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0030","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2007.07.001","article-title":"Quality assurance of dosimetry and the impact on sample size in randomized clinical trials","volume":"86","author":"Pettersen","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0040","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1154\/1\/012014","article-title":"SABR in clinical trials: what quality assurance (QA) is required and how can it be done?","volume":"1154","author":"Kron","year":"2019","journal-title":"J Phys Conf Ser"},{"key":"10.1016\/j.ejmp.2020.03.004_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejmp.2017.04.003","article-title":"The role of dosimetry audit in lung SBRT multi-centre clinical trials","volume":"44","author":"Clark","year":"2017","journal-title":"Phys Medica"},{"key":"10.1016\/j.ejmp.2020.03.004_b0050","doi-asserted-by":"crossref","first-page":"20170737","DOI":"10.1259\/bjr.20170737","article-title":"Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel), a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer","volume":"91","author":"Kron","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.radonc.2016.12.016","article-title":"A national dosimetry audit for stereotactic ablative radiotherapy in lung","volume":"122","author":"Distefano","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0060","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0167-8140(19)30511-0","article-title":"OC-0091 patterns of failures among imaging and radiation oncology core lung and spine phantom irradiations","volume":"133","author":"Edward","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmp.2018.08.010","article-title":"An end-to-end postal audit test to examine the coincidence between the imaging isocenter and treatment beam isocenter of the IGRT linac system for Japan Clinical Oncology Group (JCOG) clinical trials","volume":"53","author":"Kumazaki","year":"2018","journal-title":"Phys Medica"},{"key":"10.1016\/j.ejmp.2020.03.004_b0070","article-title":"A multidisciplinary evaluation of a web-based elearning training programme for SAFRON II (TROG 13.01): a multicentre randomised study of stereotactic radiotherapy for lung metastases","author":"Pham","year":"201628","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00066-018-1383-2","article-title":"SBRT planning for spinal metastasis: indications from a large multicentric studySBRT-Planung bei Wirbels\u00e4ulenmetastasen: Indikationen aus einer gro\u00dfen Multizenterstudie","volume":"195","author":"Esposito","year":"2018","journal-title":"Strahlentherapie Und Onkol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0080","article-title":"dosimetric multicenter planning comparison studies for SBRT: methodology and future perspectives","author":"Giglioli","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejmp.2020.03.004_b0085","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejmp.2015.09.009","article-title":"Multicentre treatment planning inter-comparison in a national context: The liver stereotactic ablative radiotherapy case","volume":"32","author":"Esposito","year":"2016","journal-title":"Phys Medica"},{"key":"10.1016\/j.ejmp.2020.03.004_b0090","doi-asserted-by":"crossref","unstructured":"Mitchell P, Siva S, Kok PS, O\u2019Byrne K, Yeung A, Livingstone A, et al. NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy. J Clin Oncol 2017; 35: TPS9097\u2013TPS9097. doi:10.1200\/JCO.2017.35.15_suppl.TPS9097.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS9097"},{"key":"10.1016\/j.ejmp.2020.03.004_b0095","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/1754-9485.12336","article-title":"Guidelines for safe practice of stereotactic body (ablative) radiation therapy","volume":"59","author":"Foote","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/acm2.12146","volume":"18","author":"Halvorsen","year":"2017","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ejmp.2020.03.004_b0105","doi-asserted-by":"crossref","DOI":"10.1118\/1.3597834","article-title":"High dose per fraction dosimetry of small fields with Gafchromic EBT2 film","volume":"38","author":"Hardcastle","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.ejmp.2020.03.004_b0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.ejmp.2020.03.004_b0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phro.2019.08.005","article-title":"Dose to medium in head and neck radiotherapy: clinical implications for target volume metrics","volume":"11","author":"Hardcastle","year":"2019","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0120","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1088\/0031-9155\/51\/19\/015","article-title":"Clinical comparison of head and neck and prostate IMRT plans using absorbed dose to medium and absorbed dose to water","volume":"51","author":"Dogan","year":"2006","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ejmp.2020.03.004_b0125","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/777\/1\/012017","article-title":"Patient specific quality control for Stereotactic Ablative Body Radiotherapy (SABR): It takes more than one phantom","volume":"777","author":"Kron","year":"2017","journal-title":"J. Phys. Conf. Ser."}],"container-title":["Physica Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179720300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179720300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:36:26Z","timestamp":1761104186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1120179720300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"alternative-id":["S1120179720300594"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmp.2020.03.004","relation":{},"ISSN":["1120-1797"],"issn-type":[{"value":"1120-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial","name":"articletitle","label":"Article Title"},{"value":"Physica Medica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmp.2020.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica.","name":"copyright","label":"Copyright"}]}}